You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

rare cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumors Trial run by the NCI (Nilotinib and Paclitaxel)

Recruiting
  • Neoplasms
  • Nilotinib and Paclitaxel
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 19, 2023

Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial (biological, procedure, drug)

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • Refractory Malignant Solid Neoplasm
  • Atezolizumab
  • +5 more
  • (no location specified)
Feb 4, 2023

Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphoid System Tumor, Malignant Solid Tumor Trial run by the National Cancer

Recruiting
  • Adrenal Gland Pheochromocytoma
  • +3 more
  • Computed Tomography
  • +2 more
  • Bethesda, Maryland
  • +1 more
Jan 3, 2023

NTRK Gene Fusion - Positive Advanced or Recurrent Solid

Recruiting
  • Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
  • Larotrectinib (Vitrakvi, BAY2757556)
  • Multiple Locations, Japan
    Many locations
Jan 20, 2023

Rare Malignant Tumor Trial (Imatinib)

Not yet recruiting
  • Rare Malignant Neoplasm
  • (no location specified)
Nov 1, 2023

Carcinoma, Renal Cell, Head and Neck Tumor, Skin Tumors Trial in Villejuif (Nivolumab)

Active, not recruiting
  • Carcinoma, Renal Cell
  • +5 more
  • Villejuif, France
    Gustave Roussy Cancer Campus
Mar 28, 2022

Sarcoma, Ovarian Tumor, CNS Tumor Trial in Villejuif (Pembrolizumab)

Active, not recruiting
  • Sarcoma
  • +6 more
  • Villejuif, France
    Gustave Roussy Cancer Campus
Mar 28, 2022

Study on Gynecological Rare Cancers

Recruiting
  • Gynecologic Cancer
  • chemotherapy, surgery
  • Milan, Italy
  • +1 more
Feb 21, 2023

Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site Trial in Cambridge (FoundationOne CDx and FoundationOne Liquid

Recruiting
  • Rare Cancers
  • +2 more
  • FoundationOne CDx and FoundationOne Liquid CDx
  • Cambridge, Massachusetts
    TargetCancer Foundation
Oct 13, 2021

PSMA-PET Imaging of Salivary Gland Tumours and Other Rare

Recruiting
  • Salivary Gland Tumor
  • Rare Malignant Neoplasm
  • 68-Ga PSMA PET scan
  • Singapore, Singapore
    National Cancer Centre Singapore
Oct 11, 2022

Urothelial Cancer and Rare Genitourinary Tract Malignancies

Recruiting
  • Urothelial Cancer
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    Cognitive Burden Trial in Chapel Hill (Artificial Intelligence)

    Not yet recruiting
    • Cognitive Burden
    • Artificial Intelligence
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center
    Aug 29, 2023

    Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor Trial in Gent, Leuven, Liège (Abemaciclib, Letrozole)

    Not yet recruiting
    • Low Grade Serous Ovarian Carcinoma
    • Adult Type Granulosa Cell Tumor
    • Gent, Oost-Vlaanderen, Belgium
    • +2 more
    May 12, 2023

    NSCLC Trial in Guangzhou (Neratinib tablets)

    Not yet recruiting
    • NSCLC
    • Neratinib tablets
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 1, 2023

    Attention and Interpretation Modification for Fear of Cancer

    Recruiting
    • Breast Cancer
    • Rare Cancer
    • AIM materials and assessments
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Dec 12, 2022

    Rare Tumors and Cancer Predisposition in Individuals and

    Recruiting
    • Cancer
    • +3 more
      • Bethesda, Maryland
      • +1 more
      Aug 24, 2022

      Rare Cancers, Multiomics Trial in Heidelberg

      Recruiting
      • Rare Cancers
      • Multiomics
        • Heidelberg, Germany
          German Cancer Research Center
        May 2, 2023

        NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

        Recruiting
        • Non-Small Cell Lung Cancer
        • +5 more
        • Toripalimab
        • +3 more
        • Guanzhou, Guangdong, China
          Guangdong Lung Cancer Institute, Guangdong Provincial People's H
        Apr 4, 2023

        Rare CNS Tumors Outcomes &Risk

        Recruiting
        • High Grade Meningioma
        • +4 more
          • Bethesda, Maryland
            National Cancer Institute (NCI)
          Jul 6, 2022

          HER2 Mutant NSCLC Trial (Pyrotinib maleate)

          Not yet recruiting
          • HER2 Mutant Non-small Cell Lung Cancer
          • Pyrotinib maleate
          • (no location specified)
          Jun 6, 2022

          Ontario-wide Cancer TArgeted Nucleic Acid Evaluation

          Recruiting
          • Breast Cancer
          • +10 more
            • Hamilton, Ontario, Canada
            • +6 more
            Apr 21, 2022

            Rare Malignant Tumor Trial in Chuo-ku

            Recruiting
            • Rare Malignant Neoplasm
              • Chuo-ku, Tokyo, Japan
                National Cancer Center Hospital, Japan
              Jan 19, 2022

              Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Tumor Trial in Australia (Ipilimumab,

              Recruiting
              • Advanced Biliary Tract Cancer
              • +3 more
              • Albury, New South Wales, Australia
              • +11 more
              Oct 31, 2022

              Microsatellite High Cancers, Peritoneal Mesothelioma, Extrapulmonary High Grade Trial in Houston (XmAb20717)

              Recruiting
              • Microsatellite High Cancers
              • +7 more
              • Houston, Texas
                M D Anderson Cancer Center
              Aug 8, 2022

              Treatment in Carriers of Rare Germline Mutations

              Recruiting
              • Prostate Cancer
                • Sutton, Surrey, United Kingdom
                  Institute of Cancer Research and Royal Marsden Hospital
                Mar 30, 2022